Characteristic | No. of trials (%) |
---|---|
Study design | Â |
   Parallel | 49 (96) |
   Factorial | 2 (4) |
Number of arms | Â |
   2 arms | 38 (75) |
   3 arms | 8 (16) |
   4 arms | 2 (4) |
   5 arms | 3 (6) |
No. of participants | Â |
   Total number of participants in all trials | 48,323 |
Mean number of participants per trial (excluding outlier involving 14,802 participants) | 670 |
   Median number of participants per trial (IQR) | 457 (212 to 806) |
Trials achieving sample size | Â |
   Trials achieving at least required sample size | 18 (35%) |
   Trials recruiting 80% of original target | 34 (67%) |
Intervention evaluated | Â |
   Service Delivery | 11 (22) |
   Surgery | 8 (16) |
   Psychological Therapy | 5 (10) |
   Physical Therapies | 5 (10) |
   Diagnostic | 5 (10) |
   Drug | 4 (8) |
   Devices | 4 (8) |
   Social Care | 3 (6) |
   Education and Training | 2 (4) |
   Complementary Therapies | 2 (4) |
   Vaccines and Biologicals | 1 (2) |
   Diet | 1 (2) |
Disease (ICD10 chapter) | Â |
M00-M99 Diseases of the musculoskeletal system and connective tissue | 8 (16) |
G00-G99 Diseases of the nervous system | 8 (16) |
I00-I99 Diseases of the circulatory system | 8 (16) |
Z00-Z99 Factors influencing health status and contact with health services | 6 (12) |
F00-F99 Mental and behavioural disorders | 6 (12) |
O00-O99 Pregnancy, childbirth and the puerperium | 4 (8) |
K00-K93 Diseases of the digestive system | 3 (6) |
N00-N99 Diseases of the genitourinary system, | 3 (6) |
C00-D48 Neoplasms | 2 (4) |
LOO-L99 Diseases of the skin and subcutaneous tissue | 1 (2) |
P00-P96 Certain conditions originating in the perinatal Period | 1 (2) |
S00-T98 Injury, poisoning and certain other consequences of external causes | 1 (2) |
Primary outcome types in the 51 trials* | Â |
   Symptom score or measurement of depression/pain | 13 (25) |
   Quality of life measure (including generic and disease specific) | 10 (19) |
   Positive event rate (e.g. improvement in symptoms) | 10 (19) |
   Adverse event rate (e.g. post operative nausea and vomiting) | 9 (17) |
   Survival/mortality | 6 (11) |
   Measurement of function | 4 (8) |
   Other | 1 (2) |
Intention to treat analysis | Â |
   Yes | 48 (94) |
   No | 0 (0) |
   Unclear | 3 (6) |
Blinding / Masking | Â |
   Participant blinded | 2 (4) |
   Outcome assessor blinded | 13 (25) |
   Person administering intervention blinded | 1 (2) |
   No blinding | 38 (74) |
Combination of blinding / masking | Â |
   Participant and outcome assessor blinded only | 2 (4) |
   Administrator and outcome assessor blinded only | 1 (2) |
   Outcome assessor blinded only | 10 (20) |
   No blinding | 38 (74) |